In order to sustain fast growth, cancer cells need to take up nutrients at a faster rate than healthy cells. The human glutamine transporter ASCT2 allows the amino acid glutamine to enter cells and ASCT2 (image) is upregulated in many types of cancer cells, which need more glutamine. It is a potential target for new anti-cancer drugs. Researchers at the University of Groningen in the Netherlands have now elucidated a structure of the human ASCT2 that provides unprecedented insight into the workings of this protein, and may aid the development of drugs. The results were published in Nature Communications on July 31, 2019. The open-access article is titled “A One-Gate Elevator Mechanism for the Human Neutral Amino Acid Transporter ASCT2.” This work allowed the researchers to solve a long-lasting riddle. It was known that these transporters work like an elevator, where the substrate glutamine is engulfed by the protein, and then carried over a long distance through the cell membrane from the outside to the inside of the cell. While it was known how the substrate enters the elevator on the outside, it remained enigmatic what happens on the inside. This study now shows, for the first time, how the transported glutamine is released into the cytoplasm of the cell. The release mechanism is surprisingly similar to its catch mechanism on the outside of the cell. The same gate - a.k.a. elevator door - is used on either side of the membrane. "Hence, we have named the transport mechanism a 'one-gate elevator,” which sets it apart from the more commonly observed mechanisms that use two different gates for entry and release,” author Dr. Dirk Slotboom says. Senior author Dr. Cristina Paulino said, "This observation is of great fundamental interest, but also has potential implications for drug design.
Login Or Register To Read Full Story